• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Legal Correspondent

Advertisement

Chennai Feb.23 A Division Bench of the Madras High Court, which has been hearing a batch of petitions by Norvartis AG against challenging the rejection of its patent application by the Assistant Registrar for beta crystalline form of imatinib mesylate, vis-à-vis validity of Section 3(d) of the Indian Patents Act, 1970, on Friday decided to refer to the Chief Justice, for orders, the issue of converting the writ petitions into writ appeals.

The Bench, comprising Mr Justice R. Balasubramanian and Mrs Justice Prabha Sridevan, had already heard the views on the subject of Mr Shanthi Bhushan, senior counsel for the Company. According to him, the question of adopting a different nomenclature was immaterial, more so when the Court had jurisdiction.

More Stories on : Courts/Legal Issues | IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
El Nino dies out `earlier than normal'

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line